EcoDrugPlus

Nucleophosmin 1

Ensembl ID : ENSOPRG00000007381
Gene Symbol: NPM1
1 Cross references
409 Possible Orthologues:

Nucleotide Binding Oligomerization Domain Containing 2

Ensembl ID : ENSOPRG00000000859
Gene Symbol: NOD2
1 Cross references
166 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSOPRG00000015275
Gene Symbol: OPRK1
1 Cross references
262 Possible Orthologues:

Opioid Receptor Mu 1

Ensembl ID : ENSOPRG00000011512
Gene Symbol: OPRM1
1 Cross references
214 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSOPRG00000003503
Gene Symbol: OXTR
3 Cross references
262 Possible Orthologues:

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSOPRG00000005042
Gene Symbol: PTH1R
1 Cross references
196 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Delta

Ensembl ID : ENSOPRG00000015187
Gene Symbol: PPARD
3 Cross references
418 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Gamma

Ensembl ID : ENSOPRG00000003439
Gene Symbol: PPARG
1 Cross references
405 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSOPRG00000016766
Gene Symbol: PIK3CA
1 Cross references
275 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta

Ensembl ID : ENSOPRG00000001614
Gene Symbol: PIK3CD
1 Cross references
213 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma

Ensembl ID : ENSOPRG00000005253
Gene Symbol: PIK3CG
1 Cross references
213 Possible Orthologues:

Phosphodiesterase 10a

Ensembl ID : ENSOPRG00000000100
Gene Symbol: PDE10A
1 Cross references
205 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).